Lilly posts Phase 2b retatrutide renal results; registers tersolisib kidney PK study
Eli Lilly reported completed Phase 2b results for retatrutide in kidney disease patients and posted a new Phase 1 trial for tersolisib in participants with renal impairment.
Two Eli Lilly-related trial records were updated for the week of November 9, 2026.
- Retatrutide (LY3437943), Phase 2b, completed: This trial tested retatrutide's effect on renal function in people with overweight or obesity and chronic kidney disease, with or without type 2 diabetes.1 The study enrolled 146 participants and used a randomized, double-blind design comparing retatrutide to placebo.1 Results were first posted November 9, 2026, with primary completion listed as October 1, 2025.
- Tersolisib (LY4064809, also known as STX-478), Phase 1, not yet recruiting: Sponsored by Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company2, this study will measure how much tersolisib gets into the bloodstream and how long it takes the body to eliminate it in participants with kidney impairment compared to those with normal kidney function.2 The trial plans to enroll 32 participants2 across groups with normal, moderate, and severe renal impairment, with an estimated start in November 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.